Previous Article | Next Article 
Infection and Immunity, November 1999, p. 5877-5884, Vol. 67, No. 11
0019-9567/99/$04.00+0
Protection of Mice against Brucellosis by
Vaccination with Brucella melitensis
WR201(16M
purEK)
David L.
Hoover,1,*
Robert M.
Crawford,2,
Lillian L.
Van De
Verg,1,
Mina J.
Izadjoo,2
Apurba K.
Bhattacharjee,1
Chrysanthi M.
Paranavitana,1
Richard L.
Warren,1,§
Mikeljon P.
Nikolich,1 and
Ted L.
Hadfield3
Department of Bacterial Diseases, Walter Reed
Army Institute of Research, Washington, D.C.
20307-5100,1 and American Registry of
Pathology2 and Department of
Infectious and Parasitic Diseases,3 Armed
Forces Institute of Pathology, Washington, D.C. 20306-6000
Received 12 April 1999/Returned for modification 23 June
1999/Accepted 30 August 1999
Human brucellosis can be acquired from infected animal tissues by
ingestion, inhalation, or contamination of the conjunctiva or
traumatized skin by infected animal products. A vaccine to protect
humans from occupational exposure or from zoonotic infection in
areas where the disease is endemic would reduce an important cause of
morbidity worldwide. Vaccines currently used in animals are unsuitable
for human use. We tested a live, attenuated, purine-auxotrophic mutant
strain of Brucella melitensis, WR201, for its ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M. Mice
inoculated intraperitoneally with WR201 made serum antibody to
lipopolysaccharide and non-O-polysaccharide antigens. Splenocytes from
immunized animals released interleukin-2 (IL-2), gamma interferon, and
IL-10 when cultured with Brucella antigens. Immunization
led to protection from disseminated infection but had only a slight
effect on clearance of the challenge inoculum from the lungs. These
studies suggest that WR201 should be further investigated as a vaccine
to prevent human brucellosis.
*
Corresponding author. Mailing address: Department of
Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20307-5100. Phone: (301) 319-9573. Fax: (301) 319-9123. E-mail: david.hoover{at}na.amedd.army.mil.

Present address: Hemagen Diagnostics, Inc., Columbia, MD
21045.

Present address: JVAP, Fort Detrick, MD 21702-5041.
§
Present address: Dugway Proving Grounds, Dugway, UT
84022.
Infection and Immunity, November 1999, p. 5877-5884, Vol. 67, No. 11
0019-9567/99/$04.00+0
This article has been cited by other articles:
-
Kahl-McDonagh, M. M., Arenas-Gamboa, A. M., Ficht, T. A.
(2007). Aerosol Infection of BALB/c Mice with Brucella melitensis and Brucella abortus and Protective Efficacy against Aerosol Challenge. Infect. Immun.
75: 4923-4932
[Abstract]
[Full Text]
-
Bhattacharjee, A. K., Izadjoo, M. J., Zollinger, W. D., Nikolich, M. P., Hoover, D. L.
(2006). Comparison of Protective Efficacy of Subcutaneous versus Intranasal Immunization of Mice with a Brucella melitensis Lipopolysaccharide Subunit Vaccine.. Infect. Immun.
74: 5820-5825
[Abstract]
[Full Text]
-
Alcantara, R. B., Read, R. D. A., Valderas, M. W., Brown, T. D., Roop, R. M. II
(2004). Intact Purine Biosynthesis Pathways Are Required for Wild-Type Virulence of Brucella abortus 2308 in the BALB/c Mouse Model. Infect. Immun.
72: 4911-4917
[Abstract]
[Full Text]
-
Izadjoo, M. J., Bhattacharjee, A. K., Paranavitana, C. M., Hadfield, T. L., Hoover, D. L.
(2004). Oral Vaccination with Brucella melitensis WR201 Protects Mice against Intranasal Challenge with Virulent Brucella melitensis 16M. Infect. Immun.
72: 4031-4039
[Abstract]
[Full Text]
-
Bermudez-Humaran, L. G., Langella, P., Cortes-Perez, N. G., Gruss, A., Tamez-Guerra, R. S., Oliveira, S. C., Cardenas, O. S., Montes de Oca-Luna, R., Le Loir, Y.
(2003). Intranasal Immunization with Recombinant Lactococcus lactis Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production. Infect. Immun.
71: 1887-1896
[Abstract]
[Full Text]
-
Rouot, B., Alvarez-Martinez, M.-T., Marius, C., Menanteau, P., Guilloteau, L., Boigegrain, R.-A., Zumbihl, R., O'Callaghan, D., Domke, N., Baron, C.
(2003). Production of the Type IV Secretion System Differs among Brucella Species as Revealed with VirB5- and VirB8-Specific Antisera. Infect. Immun.
71: 1075-1082
[Abstract]
[Full Text]
-
Ko, J., Splitter, G. A.
(2003). Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans. Clin. Microbiol. Rev.
16: 65-78
[Abstract]
[Full Text]
-
Bhattacharjee, A. K., Van De Verg, L., Izadjoo, M. J., Yuan, L., Hadfield, T. L., Zollinger, W. D., Hoover, D. L.
(2002). Protection of Mice against Brucellosis by Intranasal Immunization with Brucella melitensis Lipopolysaccharide as a Noncovalent Complex with Neisseria meningitidis Group B Outer Membrane Protein. Infect. Immun.
70: 3324-3329
[Abstract]
[Full Text]
-
Pasquali, P., Adone, R., Gasbarre, L. C., Pistoia, C., Ciuchini, F.
(2001). Mouse Cytokine Profiles Associated with Brucella abortus RB51 Vaccination or B. abortus 2308 Infection. Infect. Immun.
69: 6541-6544
[Abstract]
[Full Text]
-
Izadjoo, M. J., Polotsky, Y., Mense, M. G., Bhattacharjee, A. K., Paranavitana, C. M., Hadfield, T. L., Hoover, D. L.
(2000). Impaired Control of Brucella melitensis Infection in Rag1-Deficient Mice. Infect. Immun.
68: 5314-5320
[Abstract]
[Full Text]